Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites

Bioorg Med Chem Lett. 2015 Feb 1;25(3):462-5. doi: 10.1016/j.bmcl.2014.12.048. Epub 2014 Dec 20.

Abstract

A set of compounds, previously selected as potent Hsp90α inhibitors, has been studied on a panel of human parasites. 5-Aryl-3,4-isoxazolediamide derivatives (1) were active against two protozoa, Trypanosoma brucei rhodesiense and Plasmodium falciparum, with a good tolerability toward cytotoxicity on non-malignant L6 rat myoblast cell line, unlike the 1,5-diaryl,4-carboxamides-1,2,3-triazole derivatives (2) which, while showing a single-digit nM range activity against the same protozoa, were also highly cytotoxic on L6 cells. In a subsequent in vivo study, two isoxazolediamide derivatives, 1a and 1b, were very efficacious on the sleeping sickness-causing agent with a clear parasitaemia during treatment. These data, however, showed that not all protozoa are sensitive to Hsp90 inhibitors, as well as not all Hsp90 inhibitors are equally active on parasites.

Keywords: 1,2,3-Triazole; 3,4-Isoxazolediamide; Heat shock protein inhibitors; Hsp90 inhibitors; Plasmodium falciparum; Trypanosoma brucei rhodesiense.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / chemistry*
  • Antiprotozoal Agents / pharmacology*
  • Antiprotozoal Agents / therapeutic use
  • Cell Line, Tumor
  • Disease Models, Animal
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Mice
  • Parasitemia / drug therapy
  • Plasmodium falciparum / drug effects*
  • Protein Binding
  • Rats
  • Triazoles / chemistry
  • Triazoles / pharmacology
  • Triazoles / therapeutic use
  • Trypanosoma brucei rhodesiense / drug effects*

Substances

  • Antiprotozoal Agents
  • HSP90 Heat-Shock Proteins
  • Triazoles